• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I 型遗传性酪氨酸血症患者中断恩替卡韦治疗后出现严重神经系统危象。

Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.

机构信息

Department of General Pediatrics, University Children's Hospital, Moorenstrasse 5, 40225, Düsseldorf, Germany.

出版信息

J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S223-5. doi: 10.1007/s10545-008-0807-z. Epub 2008 May 20.

DOI:10.1007/s10545-008-0807-z
PMID:18500574
Abstract

Neurological crises do not occur in patients with tyrosinaemia type I treated with NTBC. We report an 8 month-old boy with severe neurological crisis after interruption of NTBC treatment including progressive ascending polyneuropathy and diaphragmatic paralysis, arterial hypertension, respiratory distress requiring mechanical ventilation who later also developed impaired liver function and tubulopathy. After re-introduction of NTBC the patient slowly regained normal neurological functions and recovered completely.

摘要

神经危象不会发生在接受 NTBC 治疗的酪氨酸血症 I 型患者中。我们报告了一例 8 月龄男孩,在中断 NTBC 治疗后出现严重的神经危象,包括进行性上升性多发性神经病和膈肌麻痹、动脉高血压、需要机械通气的呼吸窘迫,后来还出现肝功能和肾小管病受损。重新引入 NTBC 后,患者的神经功能逐渐恢复正常并完全康复。

相似文献

1
Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.I 型遗传性酪氨酸血症患者中断恩替卡韦治疗后出现严重神经系统危象。
J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S223-5. doi: 10.1007/s10545-008-0807-z. Epub 2008 May 20.
2
Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended.
Eur J Pediatr. 2011 Jun;170(6):819. doi: 10.1007/s00431-011-1419-4. Epub 2011 Feb 22.
3
Tyrosinemia type I: Case series with response to treatment to NTBC.I型酪氨酸血症:对NTBC治疗有反应的病例系列
Indian J Gastroenterol. 2016 May;35(3):229-31. doi: 10.1007/s12664-016-0650-3. Epub 2016 Apr 25.
4
In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.简而言之:用于遗传性酪氨酸血症的尼替西农(奥法迪恩)。
Med Lett Drugs Ther. 2016 Oct 10;58(1505):e132.
5
Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?临床实践。NTBC 疗法治疗 1 型酪氨酸血症:多少才足够?
Eur J Pediatr. 2010 Jun;169(6):689-93. doi: 10.1007/s00431-009-1090-1. Epub 2009 Oct 31.
6
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.对接受2-(2-硝基-4-三氟甲基苯甲酰基)-1,3-环己二酮(NTBC)治疗的I型酪氨酸血症患者进行眼科随访。
J Inherit Metab Dis. 2003;26(1):13-6. doi: 10.1023/a:1024011110116.
7
Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.1 型酪氨酸血症患者每日测定 NTBG 及其与丁二酮的变化,比较每日单剂量与双剂量。
J Inherit Metab Dis. 2018 Mar;41(2):181-186. doi: 10.1007/s10545-017-0112-9. Epub 2017 Nov 23.
8
Single dose NTBC-treatment of hereditary tyrosinemia type I.I型遗传性酪氨酸血症的单次剂量 NTBC 治疗。
J Inherit Metab Dis. 2012 Sep;35(5):831-6. doi: 10.1007/s10545-012-9450-9. Epub 2012 Feb 4.
9
Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.在遗传性1型酪氨酸血症小鼠短期停用尼替西农后,氧化应激、谷胱甘肽代谢和肝脏再生途径被激活。
Genes (Basel). 2020 Dec 22;12(1):3. doi: 10.3390/genes12010003.
10
Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.
J Inherit Metab Dis. 2005;28(1):103-6. doi: 10.1007/s10545-005-5085-4.

引用本文的文献

1
An Unusual Presentation of Tyrosinemia Type 1 in a Pediatric Patient: Case Report and Comprehensive Review.一名儿科患者的1型酪氨酸血症异常表现:病例报告及全面综述
Clin Case Rep. 2025 Apr 1;13(4):e70384. doi: 10.1002/ccr3.70384. eCollection 2025 Apr.
2
Severe neurological crisis in adult patients with Tyrosinemia type 1.1 型酪氨酸血症成人患者的严重神经危象。
Ann Clin Transl Neurol. 2020 Sep;7(9):1732-1737. doi: 10.1002/acn3.51160. Epub 2020 Aug 21.
3
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.

本文引用的文献

1
Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?用NTBC治疗的I型酪氨酸血症:甲胎蛋白如何预测肝癌?
Mol Genet Metab. 2006 Dec;89(4):310-5. doi: 10.1016/j.ymgme.2006.07.009. Epub 2006 Sep 27.
2
Human Gene Mutation Database (HGMD): 2003 update.人类基因突变数据库(HGMD):2003年更新版。
Hum Mutat. 2003 Jun;21(6):577-81. doi: 10.1002/humu.10212.
3
The pathophysiology and treatment of hereditary tyrosinemia type 1.1型遗传性酪氨酸血症的病理生理学与治疗
1 型酪氨酸血症的药物治疗的长期结果和实际考虑
Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364-4.
4
Unusual first presentation of a metabolic disorder.一种代谢紊乱的不寻常首发表现。
BMJ Case Rep. 2019 Mar 22;12(3):e226716. doi: 10.1136/bcr-2018-226716.
5
Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.酪氨酸血症停用尼替西农(NTBC)治疗后的神经危机
Iran J Child Neurol. 2017 Fall;11(4):66-70.
6
A Case Report of a Very Rare Association of Tyrosinemia type I and Pancreatitis Mimicking Neurologic Crisis of Tyrosinemia Type I.1型酪氨酸血症与酷似1型酪氨酸血症神经危机的胰腺炎罕见关联的病例报告
Balkan Med J. 2016 May;33(3):370-2. doi: 10.5152/balkanmedj.2016.141074. Epub 2016 May 1.
7
Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.1型酪氨酸血症与停用尼替西农1个月后出现的不可逆神经危机
Metab Brain Dis. 2016 Oct;31(5):1181-3. doi: 10.1007/s11011-016-9833-y. Epub 2016 May 17.
8
Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.168例肝肾型酪氨酸血症患者的横断面研究及其对临床实践的意义。
Orphanet J Rare Dis. 2014 Aug 1;9:107. doi: 10.1186/s13023-014-0107-7.
9
Recommendations for the management of tyrosinaemia type 1.推荐 1 型酪氨酸血症的管理。
Orphanet J Rare Dis. 2013 Jan 11;8:8. doi: 10.1186/1750-1172-8-8.
10
Single dose NTBC-treatment of hereditary tyrosinemia type I.I型遗传性酪氨酸血症的单次剂量 NTBC 治疗。
J Inherit Metab Dis. 2012 Sep;35(5):831-6. doi: 10.1007/s10545-012-9450-9. Epub 2012 Feb 4.
Semin Liver Dis. 2001 Nov;21(4):563-71. doi: 10.1055/s-2001-19035.
4
Tyrosinemia: a review.酪氨酸血症:综述
Pediatr Dev Pathol. 2001 May-Jun;4(3):212-21. doi: 10.1007/s100240010146.
5
Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.遗传性I型酪氨酸血症:一种新的临床分类,饮食治疗的预后存在差异。
Hepatology. 1994 Nov;20(5):1187-91.
6
Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia.遗传性酪氨酸血症中肝脏疾病先于氨基酸异常出现的证据。
N Engl J Med. 1983 May 26;308(21):1265-7. doi: 10.1056/NEJM198305263082105.
7
Neurologic crises in hereditary tyrosinemia.遗传性酪氨酸血症中的神经危机
N Engl J Med. 1990 Feb 15;322(7):432-7. doi: 10.1056/NEJM199002153220704.
8
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.通过抑制4-羟基苯丙酮酸双加氧酶治疗I型遗传性酪氨酸血症。
Lancet. 1992 Oct 3;340(8823):813-7. doi: 10.1016/0140-6736(92)92685-9.
9
On the enzymic defects in hereditary tyrosinemia.关于遗传性酪氨酸血症中的酶缺陷
Proc Natl Acad Sci U S A. 1977 Oct;74(10):4641-5. doi: 10.1073/pnas.74.10.4641.